Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib and Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05083208Phase 1Terminated
- Sponsor
- Henan Cancer Hospital
- Start
- Feb 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of parsaclisib in peripheral T-cell lymphoma (PTCL), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate at 2 years. Started Feb 2022; status: terminated.
02
Drugs
parsaclisib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05083208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083208.